NBIX — Neurocrine Biosciences Share News
0.000.00%
Last trade - 00:00- $13.92bn
- $13.53bn
- $2.86bn
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall
U.S. STOCKS ON THE MOVE-Nebius Group, Lumentum Holdings
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug (updated)
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall
Neurocrine Biosciences, Inc reports results for the quarter ended June 30 - Earnings Summary
Neurocrine Biosciences Q2 adjusted EPS beats expectations, revenue rises on product portfolio growth
Brief: Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
Brief: Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
Brief: Neurocrine Biosciences Initiates Phase 2 Study Of Crinecerfont In Pediatric Patients Under 4 Years Old With Classic Congenital Adrenal Hyperplasia
Brief: Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics
Neurocrine Biosciences Q1 adjusted EPS beats estimates, sales up 44%
Brief: Neurocrine Biosciences Announces New Survey Results Showing Significant Burden Of Tardive Dyskinesia On Employment
Brief: Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating Nbip-'2118, A Corticotropin-Releasing Factor Type 2 Receptor Agonist
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover